| Murray Rebner, | |
|
3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 | |
| (248) 551-5122 | |
| Not Available |
| Full Name | Murray Rebner |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 44 Years |
| Location | 3601 W 13 Mile Rd, Royal Oak, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942260583 | NPI | - | NPPES |
| 300F362420 | Other | MI | BCBSM |
| 3427270 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301044042 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital Royal Oak | Royal oak, MI | Hospital |
| Beaumont Hospital - Grosse Pointe | Grosse pointe, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Beaumont Medical Group Hospital Based Services | 3072875889 | 457 |
News Archive
With the third and largest of the U.S. tobacco companies planning an e-cigarette product launch this fall, this next frontier for "Big Tobacco" provides renewed presence in a declining marketplace. It's also a potential gateway to new smokers, particularly among teens and in emerging/foreign markets, according to behavioral scientists at The University of Texas MD Anderson Cancer Center.
Today Bruker launched the new ALPHA II, the latest generation of the ALPHA series of compact FTIR spectrometers. The ALPHA II features fully-automated test routines for validation regarding operational qualification and performance validation as well as innovations in temperature-stabilized detector and high-quality IR source technology.
HCA Inc., the nation's biggest hospital operator by number of facilities, filed plans last week for a $4.6 billion initial public offering as it "looks to return to the public markets," The Wall Street Journal reports.
Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept. 11 on "Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening," which will feature a variety of cutting-edge advances in the field developed by researchers in Western New York and throughout the US.
The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.
› Verified 5 days ago
| Entity Name | Beaumont Medical Group Hospital Based Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427567858 PECOS PAC ID: 3072875889 Enrollment ID: O20180314001796 |
News Archive
With the third and largest of the U.S. tobacco companies planning an e-cigarette product launch this fall, this next frontier for "Big Tobacco" provides renewed presence in a declining marketplace. It's also a potential gateway to new smokers, particularly among teens and in emerging/foreign markets, according to behavioral scientists at The University of Texas MD Anderson Cancer Center.
Today Bruker launched the new ALPHA II, the latest generation of the ALPHA series of compact FTIR spectrometers. The ALPHA II features fully-automated test routines for validation regarding operational qualification and performance validation as well as innovations in temperature-stabilized detector and high-quality IR source technology.
HCA Inc., the nation's biggest hospital operator by number of facilities, filed plans last week for a $4.6 billion initial public offering as it "looks to return to the public markets," The Wall Street Journal reports.
Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept. 11 on "Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening," which will feature a variety of cutting-edge advances in the field developed by researchers in Western New York and throughout the US.
The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Murray Rebner, 3601 W 13 Mile Rd, 400-fsc/pcs, Royal Oak, MI 48073-6712 Ph: () - | Murray Rebner, 3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 Ph: (248) 551-5122 |
News Archive
With the third and largest of the U.S. tobacco companies planning an e-cigarette product launch this fall, this next frontier for "Big Tobacco" provides renewed presence in a declining marketplace. It's also a potential gateway to new smokers, particularly among teens and in emerging/foreign markets, according to behavioral scientists at The University of Texas MD Anderson Cancer Center.
Today Bruker launched the new ALPHA II, the latest generation of the ALPHA series of compact FTIR spectrometers. The ALPHA II features fully-automated test routines for validation regarding operational qualification and performance validation as well as innovations in temperature-stabilized detector and high-quality IR source technology.
HCA Inc., the nation's biggest hospital operator by number of facilities, filed plans last week for a $4.6 billion initial public offering as it "looks to return to the public markets," The Wall Street Journal reports.
Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept. 11 on "Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening," which will feature a variety of cutting-edge advances in the field developed by researchers in Western New York and throughout the US.
The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.
› Verified 5 days ago
Terrence Metz, Radiology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-5000 | |
Christopher W Keyes, MD Radiology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-7266 | |
Stephen Hudak, Radiology Medicare: Not Enrolled in Medicare Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-551-6262 | |
Elias Antypas, Radiology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-6509 | |
Dr. Derek Alexander Mumaw, MD Radiology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-551-6347 | |
Kent Donovan, Radiology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-6509 | |
Dr. John Douglas Ebersole, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-6064 |